Royalty Pharma plc (RPRX) and Cytokinetics (CYTK) Announce Expanded Strategic Funding Collaboration

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. APGE
5. USO
6. MU
7. HOOD
8. DFTX
9. GOOGL
10. ABBV

Go back to Royalty Pharma plc (RPRX) and Cytokinetics (CYTK) Announce Expanded Strategic Funding Collaboration

Cytokinetics (CYTK) PT Lowered to $85 at Jefferies

May 23, 2024 5:59 AM EDT

Jefferies analyst Akash Tewari lowered the price target on Cytokinetics (NASDAQ: CYTK) to $85.00 (from $95.00) while maintaining a Buy rating.

The analyst comments "CYTK announced a $500m raise + amended its terms w/ Royalty Pharma (incl. updated royalty structure for afi, loan related to Ome... More